Search  in | Advanced
   Print  
Platelets

 
IN THIS SECTION
Resources
Correspondence
Analysis

QUICK LINKS
Public Health Agency of Canada's Guideline for Investigation of Suspected Transfusion Transmitted Bacterial Contamination

Indications for Platelet Transfusion Slide Presentation

Biological Licensing Applications

Contact AABB Regulatory Affairs Department
 
Overview
Platelets, also known as thrombocytes, are very small cellular components of blood that are made in the bone marrow and survive in the circulatory system for an average of nine to 10 days. Considered a vital element of blood, platelets aid blood clotting by sticking to the lining of blood vessels, preventing possible day-to-day leakage as well as massive blood loss often associated with trauma. Platelets are used to treat a condition called thrombocytopenia as well as for patients undergoing treatment for leukemia, cancer, aplastic anemia, and marrow transplants. Platelets can be collected either from donated whole blood or by plateletpheresis. When collecting platelets from whole blood, the unit is centrifuged once to separate the platelet-rich plasma and then a second time to concentrate the platelets further. Plateletpheresis involves drawing blood from the donor into an apheresis instrument, which, using centrifugation, separates the blood into its components, retains the platelets, and returns the remainder of the blood to the donor. The resulting component contains about six times as many platelets as a unit obtained from whole blood. Platelets can be stored for only five days, unless the establishment is using an FDA-approved protocol that allows for seven-day storage.

AABB works on behalf of the transfusion medicine and cellular therapy community to ensure the safe and effective collection, processing and use of platelets. AABB works directly with federal agencies, including the Food and Drug Administration and the Centers for Medicare and Medicaid Services, to ensure appropriate guidance, regulations and reimbursement for platelets.

Recent Actions
01/29/08
Gambro BCT and Fenwall announce the suspension of the PASSPORT study as a “precautionary measure” because both interim data and published studies estimate that bacterially contaminated platelets may escape detection by culture at 24 hours and, therefore, may pose a transfusion risk.

Last modified on 6/19/2008 9:39:33 AM
What's New!
Call for AABB Award Nominations
Details
2008 AABB Annual Meeting & TXPO Online
Details
AABB Weekly Report - October 3, 2008
Details
AABB Announces 2008 Award and Scholarship Recipients
Details
The National Blood Foundation (NBF) Announces Recipients of the 2008 NBF Scientific Research Grants
Details
Association Bulletin #08-04 - Strategies to Reduce Adverse Reactions and Injuries in Younger Donors
Details
Summary of Draft Comments to be Submitted to TJC on Blood Management Performance Measures
Details
Significant Changes to the Standards for Cellular Therapy Product Services, 3rd edition
Details
First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
Details
2008 West Nile Virus Biovigilance Network
Details
List of AABB-Accredited Facilities with Approved Variances for ISBT 128
Details
Instructions on Applying for an AABB Variance
Details